Reports Q3 revenue $49.298M vs $36.062M last year. “We closed two transformational transactions during the quarter, the divestiture of our Passenger business and the acquisition of Keystone Perfusion, setting us up incredibly well for long term growth and value creation,” said Melissa Tomkiel, Co-CEO and General Counsel. “Organic revenue growth accelerated to 29.0% in Q3, well above our expectation for mid-teens revenue growth in the second half of the year, resulting in record Adjusted EBITDA performance.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTA:
- Is BLDE a Buy, Before Earnings?
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Strata Critical Medical price target raised to $7.25 from $6.50 at Lake Street
- Strata Critical Medical Completes Keystone Acquisition
- Strata completes acquisition of Keystone Perfusion